- SurModics and EGEN Announce Collaboration with Potential for
Long-term Delivery of siRNA
SurModics and EGEN Announce Collaboration with Potential for Long-term Delivery of siRNA
- Edge Therapeutics and SurModics Collaborate to Develop a Drug Delivery Technology for Treatment of Secondary Brain Injury After Stroke or Traumatic Brain Injury (TBI)
NEWARK, NJ -- (Marketwire) -- 07/20/10 -- Edge Therapeutics, Inc.,
a specialty pharmaceutical company focused on improving the delivery
of life-saving medicines to the brain announced today that it has
entered into a feasibility agreement with SurModics, Inc. (NASDAQ:
SRDX), a leading provider of drug delivery and surface modification
technologies to the healthcare industry. According to the agreement,
SurModics will develop a novel biodegradable, site-specific,
sustained-release formulation (NimoGel(TM), EG-1961) for treatment of
delayed complications of ruptured brain aneurysms or traumatic brain
injury (TBI). NimoGel, Edge's lead drug, is a combination of the
FDA-approved drug nimodipine, a calcium channel blocker, and a
proprietary biodegradable delivery system designed to be injected
delivered directly into the subarachnoid space around the brain.
"The need for effective ways to improve treatment of cerebrovascular
bleeding events has never been greater than it is today," said J.
Paul Muizelaar, MD, PhD, Professor and Chair of the Department of
Neurosurgery at the University of California at Davis and a member of
Edge Therapeutics' Scientific Advisory Board. "There is a strong
rationale for delivering nimodipine once locally to the site of the
bleed and sustain it over 14 days. If successful, this approach could
give patients a better chance of a full recovery."
- Hansen Medical Names New CEO
Frederic Moll, M.D. to Lead Board of Directors as Executive Chairman
MOUNTAIN VIEW, CA -- (Marketwire) -- 06/01/10 -- Hansen Medical,
Inc. (NASDAQ: HNSN) announced today that veteran medical device
industry executive Bruce J. Barclay will join the company as
president and chief executive officer, and a member of the Board of
Directors on June 9, 2010, and that Frederic H. Moll, M.D. has been
named executive chairman of the Board. In addition, Russell C.
Hirsch, M.D., Ph.D., will transition from his current role as
chairman of the board to lead outside director.
- OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent
OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent
|
